ReviewAntimicrobial agents and chemotherapy2016
Review of Experimental Compounds Demonstrating Anti-Toxoplasma Activity.
Review in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Concurrent Assessment of Synthetic and Natural Compounds on the Proliferation ofTropical medicine and infectious disease · 2025Article
- Review of neosporosis: Disease insights and control approaches.Open veterinary journal · 2025Review
- Inhibitors of acetohydroxyacid synthase as promising agents against non-tuberculous mycobacterial diseases.The Journal of antibiotics · 2025Article
- Discovery of potent anti-toxoplasmosis drugs from secondary metabolites in Citrus limon (lemon) leaves, supported in-silico study.Scientific reports · 2025Article
- Antimalarial Dibenzannulated Medium-Ring Keto Lactams.ACS infectious diseases · 2023Article
- The role ofFrontiers in cellular and infection microbiology · 2023Article
- A Histone Deacetylase (HDAC) Inhibitor with Pleiotropic In Vitro Anti-International journal of molecular sciences · 2022Article
- Analogs of Marinopyrrole A Show Enhancement to ObservedAntimicrobial agents and chemotherapy · 2022Article
- Toxoplasmosis and Schizophrenia: A Systematic Review and Meta-Analysis of Prevalence and Associations and Future Directions.Psychiatric research and clinical practice · 2022Article
- Toxoplasmosis: Current and Emerging Parasite Druggable Targets.Microorganisms · 2021Review
- REVIEW OF DNA VACCINE APPROACHES AGAINST THE PARASITE TOXOPLASMA GONDII.The Journal of parasitology · 2021Review
- Assessment of the Activity of Decoquinate and Its Quinoline-Molecules (Basel, Switzerland) · 2021Article
- Valproic Acid Inhibits ChronicAntimicrobial agents and chemotherapy · 2021Article
- Diaryl Ureas as an Antiprotozoal Chemotype.ACS infectious diseases · 2021Article
- Sulfonamide drugs: structure, antibacterial property, toxicity, and biophysical interactions.Biophysical reviews · 2021Review
- Article
- Neurological and Neurobehavioral Disorders Associated withJournal of parasitology research · 2021Review
- Dual-Stage Picolinic Acid-Derived Inhibitors ofACS medicinal chemistry letters · 2020Article
- Isolation of Human Small Extracellular Vesicles and Tracking of their Uptake by Retinal Pigment Epithelial Cells In Vitro.International journal of molecular sciences · 2020Article
- Interaction of apigenin-7-O-glucoside with pyrimethamine againstJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Toxoplasma gondii is a ubiquitous apicomplexan parasite capable of infecting humans and other animals. Current treatment options for T. gondii infection are limited and most have drawbacks, including high toxicity and low tolerability. Additionally, no FDA-approved treatments are available for pregnant women, a high-risk population due to transplacental infection. Therefore, the development of novel treatment options is needed. To aid this effort, this review highlights experimental compounds that, at a minimum, demonstrate inhibition of in vitro growth of T. gondii When available, host cell toxicity and in vivo data are also discussed. The purpose of this review is to facilitate additional development of anti-Toxoplasma compounds and potentially to extend our knowledge of the parasite.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.